Jazz Pharmaceuticals plc (JAZZ): what the price assumes

In the published model solve dated 2026-Q2, anchored at $257.10, Jazz Pharmaceuticals plc (JAZZ) is priced for +7.2% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/JAZZ

Headline

FieldValue
TickerJAZZ
CompanyJazz Pharmaceuticals plc
Current price$257.10/sh

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)4.8%
Operating margin (mid-cycle)16.8%
Margin compression (value-band)-12.0pp
Trailing margin (depressed year)-0.9%
Implied growth7.2%
Multiple paid26x mid-cycle operating income

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~8.9pp (computed at the 7% minimum rate; the CAPM rate 6.7% sits below it).

Reconcile: at the x-ray's 9.3% required return this reads ~5.1 years; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
vs own history-0.11σ
implied end-window share0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset14.31x2expensive
Earnings2.06x2expensive
Relative1.62x3expensive
Growth0.73x3justifies

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.8%); the inversion above states its own rate.

Per-Model Detail (n=10)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$585.670.44xyesFCF base $1.4B, growth 10% (input: historical growth), terminal g 4.0%, WACC 7.8%, 6yr projection
DCF Exit MultipleGrowth$352.540.73xyesExit EV/EBITDA: 21.4x / 23.4x / 25.4x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$92.162.79xyesP/E 52.8x (blended: static sector reference 24x + trailing (TTM) 576x), scenarios: 43.8x / 52.8x / 61.8x (bear / base = reference held flat / bull), EV/EBITDA 16x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$4.8253.34xyesBV/sh $68.57, ROE (TTM) 0.7%, ke 9.3% (excluded from median)
Two-Stage Excess ReturnAsset$2.50102.84xyes5yr excess ROE then converge to ke=9.3% (excluded from median)
Discounted Future Market CapGrowth$223.171.15xyesRev $4.4B, growth 10% (input: historical growth; tapered), Terminal P/S: 3.2x / 3.8x / 4.5x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelative——no—
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$0.0125710.00xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.26B × (1−21%) / WACC 7.8% → EPV (no growth) (excluded from median)
Residual IncomeAsset$1.77145.25xyesBV $68.57 + 5yr PV of (ROE (TTM) 0.7% − Kₑ 9.3%) × BV; BV grows 0.4%/yr (excluded from median)
Graham NumberAsset$13.0319.73xyes√(22.5 × EPS $0.11 × BVPS $68.57) — Graham's conservative floor
EV/EBITDA RelativeRelative$158.451.62xyesEBITDA $0.88B × sector EV/EBITDA 16.0x
FCF YieldEarnings$153.821.67xyesFCF $1269.6M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$105.092.45xyesSBC-adj FCF $0.97B (FCF $1.27B − SBC $0.30B) capitalized at Kₑ
Ben Graham FormulaEarnings$0.092856.67xyesEPS $0.11 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAsset$28.918.89xyesBV $68.57 × (ROIC 3.3% / WACC 7.8%)
P/Sales SectorRelative$268.600.96xyesRevenue $4.44B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings$1.19216.05xyesEPS $0.11 / required return 9.3% (Rf 4.3% + ERP 5.0%) (excluded from median)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$2.5b
Net debt / NOPAT (after-tax)4.22x
Net debt / operating income (pre-tax)3.33x
Share count CAGR (dilution)1.2%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 16.8%); the trailing year was depressed.

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Bull Case

The market appears to be pricing Jazz as a melting ice cube, a company whose core sleep franchise faces eventual generic competition, and the fundamentals tell a more constructive story than that framing allows. The reported GAAP earnings look thin and the trailing operating line is near zero, which feeds the pessimism, but that is an accounting artifact: heavy amortization of acquired intangibles from deals like the GW Pharmaceuticals purchase that brought in Epidiolex flows through the income statement and crushes reported profit, while the cash the business actually throws off is large. Jazz generated $408 million of operating cash flow in a single quarter and reported non-GAAP adjusted EPS of $6.34. The gap between the GAAP picture the market fixates on and the cash reality is the opportunity.

The growth drivers are diversifying away from the oxybate dependence the bears emphasize. First-quarter revenue grew 19% year over year to $1.1 billion. Xywav, the lower-sodium successor to Xyrem that Jazz has deliberately steered patients toward, grew 18% with 425 net patient additions and roughly 16,600 active patients, and the company expects it to remain the leading branded oxybate. Epidiolex grew 15% on 16% volume growth, with expansion into the adult population and long-term-care settings extending its runway, and the oncology portfolio including Rylaze adds further diversification. The 10-K acknowledges the competitive landscape directly, noting the industry is "highly competitive" and that its products compete with existing therapies, but the patient additions and volume growth show the franchises are still expanding, not just defending.

The pipeline gives the bull case a near-term catalyst with real value. Zanidatamab, the HER2-targeted oncology asset, received Priority Review with a regulatory decision set for August 25, 2026, a potential approval that would meaningfully extend Jazz's oncology presence. Management reaffirmed full-year 2026 revenue guidance of $4.25 billion to $4.5 billion. The bull case is that Jazz is a cash-rich, diversifying specialty pharma whose reported earnings understate it, trading as though the sleep franchise is already in decline when the portfolio is still growing and a new oncology approval is weeks away.

Bear Case

The clearest risk in Jazz is how management deploys capital, because the company's growth has been bought as much as built, and that pattern carries a cost. Jazz has assembled its portfolio through a string of large acquisitions, the GW Pharmaceuticals deal that brought Epidiolex and more recent oncology purchases, and that strategy is exactly why the reported income statement is so distorted: the trailing operating line is near zero because the amortization of all that acquired intangible value flows through it. Each deal adds revenue but also adds debt and amortization, and it raises the recurring question of whether the prices paid will earn their cost of capital. A company that must keep acquiring to offset the eventual decline of its legacy products is on a treadmill where capital-allocation discipline is the whole game, and the market is right to demand proof rather than take it on faith.

That acquisitive strategy has loaded the balance sheet. Jazz carries about $5.4 billion of gross debt and roughly $2.5 billion of net debt, and the filings note that interest expense is not even separately broken out in a way that lets coverage be computed cleanly. Debt taken on to fund acquisitions is fine while the acquired products perform, but it removes flexibility and amplifies the downside if a pipeline asset fails or a key product faces faster-than-expected erosion. The oxybate franchise itself, however well managed, faces the structural reality that branded drugs eventually meet generic and authorized-generic competition; the company's own guidance assumes increased competitive dynamics in the sleep business in the second half of the year, including declines in Xyrem and high-sodium authorized-generic revenue.

The valuation leaves little room for a capital-allocation misstep. At $224.63 the asset and earnings-power methods land far below the price, and even the peer-multiple method sits well under it; only the forward-growth and free-cash-flow methods reach the price, and they do so by assuming the diversification works, the pipeline delivers, and the acquired assets earn their keep. The zanidatamab decision in August is binary: an approval supports the thesis, a setback would leave the stock priced for growth it did not get, on top of a debt load taken on to chase it. The 10-K is candid that its products compete in a "highly competitive" industry. The bear case is that Jazz is a serial acquirer whose reported economics are obscured by the very deals that drive its growth, carrying meaningful debt, priced for a successful continuation of a strategy that depends on management consistently paying the right price for the next franchise.

Valuation

Jazz is an elevated case where the reported earnings are nearly unusable, so the valuation turns entirely on whether you look through the acquisition accounting. At $224.63 the trailing operating line is near zero because amortization of acquired intangibles overwhelms it, which makes the earnings-power value, the excess-return methods, the residual-income method, and the Graham-style floors collapse to tiny or meaningless figures. Those are not signals that the business is worthless; they are signals that the GAAP earnings are the wrong input. The methods that look through the amortization tell a coherent story: the perpetual-growth DCF lands far above the price, the exit-multiple DCF near $326, the free-cash-flow methods above the price, and the relative-valuation method below it near $92. The framework reads only the forward-growth family as reaching the price.

The right anchor is normalized earnings and cash flow. On a mid-cycle basis the business earns an operating margin near 17% and roughly $746 million of normalized operating income, a world away from the near-zero GAAP figure, and it generated $408 million of operating cash flow in the quarter. The honest framing is that Jazz is cheap on its cash generation and expensive on its reported earnings, and the resolution depends on whether the cash keeps coming, which in turn depends on the sleep franchise holding longer than the bears fear and the newer products plus the pipeline filling the gap.

The balance sheet is the constraint that makes this more than a free option. Jazz carries about $5.4 billion of gross debt and $2.5 billion of net debt, accumulated through the acquisitions that built the portfolio, and the filings note interest expense is not separately reported in a way that allows a clean coverage calculation. The valuation verdict is that the methods looking through the amortization support a price above today's, but they rest on the assumptions that the acquired franchises perform, the debt stays serviceable from cash flow, and the August pipeline catalyst goes the right way. The cash-flow reality is the bull's strongest card; the reported earnings and the debt are why the market demands a discount to the look-through value.

Catalysts

Jazz's first quarter of 2026 beat and reframed the debate around its cash generation. Total revenue grew 19% year over year to $1.1 billion, GAAP and non-GAAP adjusted EPS came in at $4.43 and $6.34 respectively, and the company generated $408 million of operating cash flow. Xywav grew 18% with 425 net patient additions and about 16,600 active patients, and Epidiolex grew 15% on 16% volume growth, helped by expansion into adult and long-term-care settings. Management reaffirmed full-year 2026 revenue guidance of $4.25 billion to $4.5 billion, while assuming intensifying competition in the sleep business in the second half, including declines in Xyrem and high-sodium authorized-generic revenue.

The dominant near-term catalyst is regulatory: zanidatamab, the HER2-targeted oncology asset, has Priority Review with a decision date of August 25, 2026, and an approval would extend Jazz's oncology franchise and validate the diversification strategy. Beyond that, the things to watch are the trajectory of Xywav patient additions as the oxybate market faces more competition, Epidiolex's continued volume growth into new settings, the pace of debt paydown from the strong operating cash flow, and any further business-development activity, since acquisitions are central to how Jazz grows. The August decision is the binary event most likely to move the stock; the longer-term question is whether the newer products and pipeline can outgrow the eventual erosion of the legacy sleep franchise.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Jazz Q1 2026 earnings, StockTitan / Tikr, May 2026 · Jazz Q1 2026 earnings, StockTitan, May 2026 · Jazz Q1 2026 earnings, Tikr, May 2026 · Jazz Q1 2026 earnings, StockTitan / Yahoo Finance, May 2026

View the full interactive JAZZ report on boothcheck